SARTORIUS STEDIM BIOTECH (56S1.DE) Stock Fundamental Analysis
Europe - FRA:56S1 - FR0013154002 - Common Stock
195.2 EUR
+5 (+2.63%)
We assign a fundamental rating of 5 out of 10 to 56S1. 56S1 was compared to 20 industry peers in the Life Sciences Tools & Services industry. Both the profitability and the financial health of 56S1 get a neutral evaluation. Nothing too spectacular is happening here. 56S1 shows excellent growth, but is valued quite expensive already. These ratings could make 56S1 a good candidate for growth investing.
1. Profitability
1.1 Basic Checks
In the past year 56S1 was profitable.
56S1 had a positive operating cash flow in the past year.
56S1 had positive earnings in each of the past 5 years.
In the past 5 years 56S1 always reported a positive cash flow from operatings.
1.2 Ratios
The Return On Assets of 56S1 (2.71%) is worse than 61.11% of its industry peers.
56S1 has a Return On Equity (5.63%) which is in line with its industry peers.
56S1 has a Return On Invested Capital of 4.60%. This is comparable to the rest of the industry: 56S1 outperforms 44.44% of its industry peers.
56S1 had an Average Return On Invested Capital over the past 3 years of 10.41%. This is above the industry average of 7.27%.
The last Return On Invested Capital (4.60%) for 56S1 is well below the 3 year average (10.41%), which needs to be investigated, but indicates that 56S1 had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.71% | ||
| ROE | 5.63% | ||
| ROIC | 4.6% |
ROA(3y)7.81%
ROA(5y)9.13%
ROE(3y)17.3%
ROE(5y)20.06%
ROIC(3y)10.41%
ROIC(5y)14.57%
1.3 Margins
56S1 has a better Profit Margin (7.78%) than 61.11% of its industry peers.
In the last couple of years the Profit Margin of 56S1 has declined.
56S1 has a Operating Margin of 14.71%. This is comparable to the rest of the industry: 56S1 outperforms 55.56% of its industry peers.
56S1's Operating Margin has declined in the last couple of years.
56S1 has a better Gross Margin (44.63%) than 72.22% of its industry peers.
56S1's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 14.71% | ||
| PM (TTM) | 7.78% | ||
| GM | 44.63% |
OM growth 3Y-22.38%
OM growth 5Y-9.98%
PM growth 3Y-24.01%
PM growth 5Y-17.3%
GM growth 3Y-6.9%
GM growth 5Y-3.53%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), 56S1 is creating some value.
The number of shares outstanding for 56S1 has been increased compared to 1 year ago.
56S1 has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, 56S1 has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 3.96 indicates that 56S1 is not in any danger for bankruptcy at the moment.
With a decent Altman-Z score value of 3.96, 56S1 is doing good in the industry, outperforming 77.78% of the companies in the same industry.
The Debt to FCF ratio of 56S1 is 5.98, which is a neutral value as it means it would take 56S1, 5.98 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of 56S1 (5.98) is comparable to the rest of the industry.
A Debt/Equity ratio of 0.71 indicates that 56S1 is somewhat dependend on debt financing.
56S1 has a Debt to Equity ratio (0.71) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.71 | ||
| Debt/FCF | 5.98 | ||
| Altman-Z | 3.96 |
ROIC/WACC0.53
WACC8.68%
2.3 Liquidity
A Current Ratio of 1.91 indicates that 56S1 should not have too much problems paying its short term obligations.
56S1 has a better Current ratio (1.91) than 88.89% of its industry peers.
56S1 has a Quick Ratio of 1.18. This is a normal value and indicates that 56S1 is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.18, 56S1 is in line with its industry, outperforming 50.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.91 | ||
| Quick Ratio | 1.18 |
3. Growth
3.1 Past
56S1 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 25.91%, which is quite impressive.
The Earnings Per Share has been growing slightly by 4.19% on average over the past years.
56S1 shows a small growth in Revenue. In the last year, the Revenue has grown by 5.44%.
The Revenue has been growing by 14.05% on average over the past years. This is quite good.
EPS 1Y (TTM)25.91%
EPS 3Y-22.3%
EPS 5Y4.19%
EPS Q2Q%38.82%
Revenue 1Y (TTM)5.44%
Revenue growth 3Y-1.25%
Revenue growth 5Y14.05%
Sales Q2Q%5.46%
3.2 Future
Based on estimates for the next years, 56S1 will show a very strong growth in Earnings Per Share. The EPS will grow by 22.23% on average per year.
56S1 is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.45% yearly.
EPS Next Y27.61%
EPS Next 2Y23.83%
EPS Next 3Y23.3%
EPS Next 5Y22.23%
Revenue Next Year9.03%
Revenue Next 2Y9.51%
Revenue Next 3Y10.23%
Revenue Next 5Y10.45%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 47.26, the valuation of 56S1 can be described as expensive.
Compared to the rest of the industry, the Price/Earnings ratio of 56S1 indicates a slightly more expensive valuation: 56S1 is more expensive than 72.22% of the companies listed in the same industry.
56S1 is valuated expensively when we compare the Price/Earnings ratio to 27.86, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 36.37, the valuation of 56S1 can be described as expensive.
56S1's Price/Forward Earnings ratio is a bit more expensive when compared to the industry. 56S1 is more expensive than 72.22% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.32, 56S1 is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 47.26 | ||
| Fwd PE | 36.37 |
4.2 Price Multiples
56S1's Enterprise Value to EBITDA ratio is a bit more expensive when compared to the industry. 56S1 is more expensive than 77.78% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of 56S1 indicates a slightly more expensive valuation: 56S1 is more expensive than 61.11% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 38.27 | ||
| EV/EBITDA | 28.69 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
56S1's earnings are expected to grow with 23.30% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.71
PEG (5Y)11.27
EPS Next 2Y23.83%
EPS Next 3Y23.3%
5. Dividend
5.1 Amount
With a yearly dividend of 0.36%, 56S1 is not a good candidate for dividend investing.
56S1's Dividend Yield is slightly below the industry average, which is at 0.71.
Compared to an average S&P500 Dividend Yield of 2.44, 56S1's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.36% |
5.2 History
The dividend of 56S1 has a limited annual growth rate of 4.44%.
Dividend Growth(5Y)4.44%
Div Incr Years0
Div Non Decr Years1
5.3 Sustainability
29.77% of the earnings are spent on dividend by 56S1. This is a low number and sustainable payout ratio.
56S1's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP29.77%
EPS Next 2Y23.83%
EPS Next 3Y23.3%
FRA:56S1 (10/3/2025, 7:00:00 PM)
195.2
+5 (+2.63%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners11.07%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap19.00B
Analysts81.11
Price Target239.46 (22.67%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.36% |
Yearly Dividend0.71
Dividend Growth(5Y)4.44%
DP29.77%
Div Incr Years0
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.2%
Min EPS beat(2)10.22%
Max EPS beat(2)22.18%
EPS beat(4)3
Avg EPS beat(4)8.6%
Min EPS beat(4)-5.62%
Max EPS beat(4)22.18%
EPS beat(8)3
Avg EPS beat(8)-10.02%
EPS beat(12)3
Avg EPS beat(12)-13.27%
EPS beat(16)5
Avg EPS beat(16)-12.35%
Revenue beat(2)2
Avg Revenue beat(2)1.91%
Min Revenue beat(2)0.3%
Max Revenue beat(2)3.52%
Revenue beat(4)3
Avg Revenue beat(4)0.4%
Min Revenue beat(4)-5.11%
Max Revenue beat(4)3.52%
Revenue beat(8)5
Avg Revenue beat(8)-0.72%
Revenue beat(12)5
Avg Revenue beat(12)-1.47%
Revenue beat(16)8
Avg Revenue beat(16)12%
PT rev (1m)0.2%
PT rev (3m)1.05%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1.15%
EPS NY rev (1m)0%
EPS NY rev (3m)2.93%
Revenue NQ rev (1m)4.65%
Revenue NQ rev (3m)2.36%
Revenue NY rev (1m)-0.07%
Revenue NY rev (3m)0.5%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 47.26 | ||
| Fwd PE | 36.37 | ||
| P/S | 6.56 | ||
| P/FCF | 38.27 | ||
| P/OCF | 24.11 | ||
| P/B | 4.75 | ||
| P/tB | N/A | ||
| EV/EBITDA | 28.69 |
EPS(TTM)4.13
EY2.12%
EPS(NY)5.37
Fwd EY2.75%
FCF(TTM)5.1
FCFY2.61%
OCF(TTM)8.1
OCFY4.15%
SpS29.76
BVpS41.13
TBVpS-4.66
PEG (NY)1.71
PEG (5Y)11.27
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.71% | ||
| ROE | 5.63% | ||
| ROCE | 5.78% | ||
| ROIC | 4.6% | ||
| ROICexc | 5.12% | ||
| ROICexgc | 15.67% | ||
| OM | 14.71% | ||
| PM (TTM) | 7.78% | ||
| GM | 44.63% | ||
| FCFM | 17.14% |
ROA(3y)7.81%
ROA(5y)9.13%
ROE(3y)17.3%
ROE(5y)20.06%
ROIC(3y)10.41%
ROIC(5y)14.57%
ROICexc(3y)10.84%
ROICexc(5y)15.37%
ROICexgc(3y)26.31%
ROICexgc(5y)36.49%
ROCE(3y)13.07%
ROCE(5y)18.3%
ROICexcg growth 3Y-36.77%
ROICexcg growth 5Y-16.49%
ROICexc growth 3Y-43.34%
ROICexc growth 5Y-25.09%
OM growth 3Y-22.38%
OM growth 5Y-9.98%
PM growth 3Y-24.01%
PM growth 5Y-17.3%
GM growth 3Y-6.9%
GM growth 5Y-3.53%
F-Score7
Asset Turnover0.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.71 | ||
| Debt/FCF | 5.98 | ||
| Debt/EBITDA | 3.84 | ||
| Cap/Depr | 93.43% | ||
| Cap/Sales | 10.07% | ||
| Interest Coverage | 2.82 | ||
| Cash Conversion | 106.77% | ||
| Profit Quality | 220.28% | ||
| Current Ratio | 1.91 | ||
| Quick Ratio | 1.18 | ||
| Altman-Z | 3.96 |
F-Score7
WACC8.68%
ROIC/WACC0.53
Cap/Depr(3y)182.98%
Cap/Depr(5y)186.68%
Cap/Sales(3y)13.87%
Cap/Sales(5y)12.23%
Profit Quality(3y)126.76%
Profit Quality(5y)109.63%
High Growth Momentum
Growth
EPS 1Y (TTM)25.91%
EPS 3Y-22.3%
EPS 5Y4.19%
EPS Q2Q%38.82%
EPS Next Y27.61%
EPS Next 2Y23.83%
EPS Next 3Y23.3%
EPS Next 5Y22.23%
Revenue 1Y (TTM)5.44%
Revenue growth 3Y-1.25%
Revenue growth 5Y14.05%
Sales Q2Q%5.46%
Revenue Next Year9.03%
Revenue Next 2Y9.51%
Revenue Next 3Y10.23%
Revenue Next 5Y10.45%
EBIT growth 1Y7.47%
EBIT growth 3Y-23.35%
EBIT growth 5Y2.67%
EBIT Next Year92.67%
EBIT Next 3Y37.11%
EBIT Next 5Y27.7%
FCF growth 1Y202.01%
FCF growth 3Y7.94%
FCF growth 5Y22.24%
OCF growth 1Y16.41%
OCF growth 3Y5.11%
OCF growth 5Y21.32%